DDInter1763 DDInter858
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) upregulates {v} (Gene) PAN2
PAN2 {u} (Gene) is downregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) upregulates PAN2 (Gene) and PAN2 (Gene) is downregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine